title: Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.
abstract: Tumor as source of tumor associated antigens (TAA) and sentinel lymph node (SLN) configure the first interaction between the malignant disease and the patient's immune system. As consequence of this interaction, a local immune response is elicited inside the SLN. Tumor's cytokines reach the SLN conditioning its cellular microenvironment to produce local permissive immune responses. This local tolerogenic immunity is decisional because it starts a systemic also permissive immunity. The tumor progresses.To counteract this mechanism, we have designed a medical procedure to create an immunotherapeutic site (ITS) that reproduces, distantly from the tumor, a TAA source and a draining lymph node but with a cellular microenvironment conditioned to promote local protective instead of permissive immune responses. Due to ITS decisional role, this local protective immunity starts a systemic anti-tumoral immune response.In progressive ovarian cancer, we tested an ITS using the autologous thermostable hemoderivative-cancer vaccine as TAA source and granulocyte macrophage-colony stimulant factor plus etoposide, injected both at the vaccination site, as conditioner of the draining lymph node cellularity. The immunophenotyping of lymph node cell populations showed that ITS acquired a locally protective immune profile T-regulatory-cells/activated-antigen presenting-cells and systemically increased the antiprogressive effect of the tested vaccine.
authors.affiliation: PharmaBlood Inc, Department of Research and Development, North Miami Beach, Florida, USA;
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lasalvia-Prisco
authors.forename: Emilio
authors.initials: E
authors.lastname: Garcia-Giralt
authors.forename: Silvia
authors.initials: S
authors.lastname: Cucchi
authors.forename: Jesús
authors.initials: J
authors.lastname: Vázquez
authors.forename: Leonard
authors.initials: L
authors.lastname: Robinson
authors.forename: John
authors.initials: J
authors.lastname: Dalton
references.citation: Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60
references.pmid: 12750554
references.citation: Int J Cancer. 1991 Feb 20;47(4):626-32
references.pmid: 1995491
references.citation: Cancer Res. 1999 Oct 15;59(20):5160-8
references.pmid: 10537292
references.citation: Clin Exp Immunol. 1991 Jun;84(3):383-8
references.pmid: 1828396
references.citation: Clin Immunol Immunopathol. 1990 Jan;54(1):161-5
references.pmid: 2152858
references.citation: Vaccine. 2005 Apr 22;23(22):2909-21
references.pmid: 15780740
references.citation: J Immunol. 2004 Jul 15;173(2):1444-53
references.pmid: 15240741
references.citation: Am J Pathol. 2005 Nov;167(5):1301-7
references.pmid: 16251414
references.citation: Ann N Y Acad Sci. 1993 Mar 20;677:404-6
references.pmid: 8494226
references.citation: J Immunother. 1999 Mar;22(2):166-74
references.pmid: 10093041
references.citation: Cancer Res. 1992 May 1;52(9):2440-6
references.pmid: 1568214
references.citation: Immunology. 2003 Nov;110(3):304-12
references.pmid: 14632657
references.citation: Am J Clin Oncol. 1982 Dec;5(6):649-55
references.pmid: 7165009
references.citation: Med Oncol. 2006;23(1):91-104
references.pmid: 16645234
references.citation: Int J Immunopharmacol. 1990;12(1):77-88
references.pmid: 2303320
references.citation: Cancer Res. 2003 Oct 15;63(20):6956-61
references.pmid: 14583497
references.citation: Blood. 1996 Jul 1;88(1):202-10
references.pmid: 8704175
references.citation: Invest New Drugs. 1984;2(2):221-5
references.pmid: 6332093
references.citation: Cancer. 2000 Jul 15;89(2):236-41
references.pmid: 10918150
references.citation: Immunol Rev. 2002 Oct;188:147-54
references.pmid: 12445288
references.citation: Am J Pathol. 2002 Jul;161(1):19-26
references.pmid: 12107085
references.citation: J Clin Oncol. 1984 Mar;2(3):187-93
references.pmid: 6699671
references.citation: Cancer Immunol Immunother. 1989;28(2):131-5
references.pmid: 2917364
references.citation: Scand J Immunol. 1986 May;23(5):605-9
references.pmid: 2939555
references.citation: Breast Cancer Res Treat. 2006 Nov;100(2):149-60
references.pmid: 16819567
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Nucl Med. 2002 Jun;43(6):811-27
references.pmid: 12050328
references.citation: Nat Rev Immunol. 2006 Sep;6(9):659-70
references.pmid: 16932751